New pill aims to tame back inflammation in axial spondyloarthritis

NCT ID NCT07047703

Recruiting now Disease control Sponsor: Grey Wolf Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests an experimental oral drug called GRWD0715 for axial spondyloarthritis, a chronic inflammatory condition affecting the spine and pelvis. The trial starts with healthy volunteers to check safety, then moves to patients to see if the drug reduces inflammation and improves symptoms over 12 weeks. About 141 people will take part, with some receiving placebo for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GRWD0715 (an oral drug that blocks the ERAP1 enzyme)
What this could lead to: If successful, this could lead to a new daily pill treatment for axial spondyloarthritis, potentially reducing inflammation and improving symptoms.
What could go wrong: This is an early-phase trial (Phase 1/2) with small groups, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXIAL SPONDYLOARTHRITIS (AXSPA)

Contacts and locations

Locations

Amsterdam University Medical Center
RECRUITING

Amsterdam, Netherlands
ETG Lublin
RECRUITING

Lublin, Poland
La Paz University Hospital
NOT_YET_RECRUITING

Madrid, Fuencarral-El Pardo, 28046, Spain
Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center)
NOT_YET_RECRUITING

Leiden, Netherlands
Malopolskie Badania Kliniczne (MBK Clinic)
NOT_YET_RECRUITING

Krakow, Małopolska, 30-002, Poland
Pioneer Clinical Research
RECRUITING

Sydney, Australia
Reina Sofia University Hospital
NOT_YET_RECRUITING

Córdoba, Poniente Sur, 14004, Spain
Reumedika
RECRUITING

Poznan, Poland
Rheumazentrum Ruhrgebiet, Ruhr-University Bochum
RECRUITING

Bochum, Germany
The Colin Bayliss Research and Teaching Unit
RECRUITING

Perth, Australia
UZ Leuven
RECRUITING

Leuven, Belgium
University Ghent
RECRUITING

Ghent, Belgium
University hospital Parc Tauli de Sabadell
NOT_YET_RECRUITING

Sabadell, Spain
University of the Sunshine Coast (UniSC)
RECRUITING

Birtinya, Australia
University of the Sunshine Coast (UniSC)
COMPLETED

Morayfield, Australia
Universitätsklinikum Erlangen - Medizinische Klinik 3
NOT_YET_RECRUITING

Erlangen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.